JNK (c-Jun N-terminal kinase), a kinase subfamily belonging to the MAPK, is activated in response to various stress stimuli and possesses a wide variety of regulatory functions.Three isoforms of the serine/threonine protein kinase JNK family (JNK1, JNK2, and JNK3) exist. JNKs play a role in the development and progression of many pathologies, including cancer, inflammatory diseases, cardiovascular and metabolic disorders, and neurodegenerative diseases.
JNKs are triggered by a phosphorylation cascade that typically involves two different upstream kinases, the so-called MAP kinase kinase kinases (MAP3K, MKKK) and the MAP kinase kinases (MAP2K; MKK). This process is similar to that used to activate the other MAP kinases. JNKs are triggered by MKK4 and MKK7 at the MAP2K level; the former is a shared activator of the JNK and p38 MAP kinase signaling pathways. The JNK cascade is a component of a complicated signaling network since it crosses numerous other routes at different places.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V96678 | MAP4K4-IN-6 | MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC50: 80 nM). | |
|
V74394 | n-Butyl α-D-fructofuranoside | 80971-59-1 | n-Butyl α-D-fructofuranoside is extracted from the root bark of Ulmus davidiana var. |
|
V9935 | RPI-1 | 269730-03-2 | RPI-1 is an ATP-dependent RET kinase inhibitor. |
|
V104312 | SET-171 | 3052985-32-4 | SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor with significant anticancer activity and the potential to regulate lipid metabolism by inhibiting the expression of hepatic pyruvate kinase (PKL). |
|
V51131 | SP-600125-Me | 54642-23-8 | negative control for SP-600125 |
|
V1565 | Tanzisertib (CC-930) | 899805-25-5 | Tanzisertib (formerly known as CC-930,JNK-930, JNKI-1,CC 930) is a potent, specific andand orally bioavailable JNK1/JNK2/JNK3 inhibitor that has the potential to be used for the treatment of fibrotic and infammatory indications. |
|
V81525 | TAT-JBD20 (L-HIV-TAT(48–57)-PP-JBD20) | TAT-JBD20 (L-HIV-TAT(48–57)-PP-JBD20) is a JNK peptide inhibitor. | |
|
V3247 | WHI-P258 | 21561-09-1 | WHI-P258 is a potent and selective Janus kinase 3 (JAK3) inhibitor discovered from homology modeling. |
|
V0471 | SP600125 (SP600125; NSC75890) | 129-56-6 | SP600125 (SP6-00125; NSC-75890) is a cell-permeable, broad-spectrum, reversible and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with potential anticancer and anti-inflammatory activity. |
|
V3732 | AS 602801 (Bentamapimod) | 848344-36-5 | AS602801 (also known as Bentamapimod and PGL5001) is a novel, potent and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with IC50 values of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively. |
|
V0475 | Anisomycin (NSC-76712, AI 3-50846, Flagecidin, Wuningmeisu C) | 22862-76-6 | Anisomycin (Wuningmeisu C, NSC76712, AI3-50846, Flagecidin),a naturally occuringbacterial antibiotic isolated from Streptomyces griseolus, is a novel, potent and specific activator (agonist)of JNK (c-Jun N-terminal Kinase) with potential antineoplastic activity. |
|
V2722 | Tanzisertib HCl (CC-930) | 899805-25-5 | Tanzisertib HCl (also known as CC-930) is a potent, specific andand orally bioavailable JNK1/JNK2/JNK3 inhibitor that has the potential to be used for the treatment of fibrotic and infammatory indications. |
|
V51558 | Dehydrocrenatine | 26585-13-7 | β-carboline alkaloid |
|
V51546 | (-)-Zuonin A (D-Epigalbacin) | 84709-25-1 | natual lignin-based JNK inhibitor |
|
V24419 | Loureirin B | 119425-90-0 | Loureirin B is a novel and potent bioactive compound. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
